Intravitreal ranibizumab for macular edema secondary to retinal vein occlusion

Ophthalmologica

Volumn 227, Issue 3, 2012, Pages 132-138

  Kim, Moosang ^a   Yu, Seung Young ^b   Kim, Eung Suk ^e   Bae, So Hyun ^c   Park, Jung Hyun ^a   Yu, Hyeong Gon ^d   Kwak, Hyung Woo ^b  

^a Inje University   (South Korea)

^b Kyung Hee University College of Medicine   (South Korea)

^c Hallym University   (South Korea)

^d Seoul National University College of Medicine   (South Korea)

^e Eulji University   (South Korea)

Author keywords

Macular edema; Ranibizumab; Retinal vein occlusion

Indexed keywords

RANIBIZUMAB;

ADULT; ARTICLE; CLINICAL ARTICLE; FEMALE; HUMAN; MALE; PROSPECTIVE STUDY; RETINA MACULA EDEMA; RETINA VEIN OCCLUSION; RETREATMENT; SPECTRAL DOMAIN OPTICAL COHERENCE TOMOGRAPHY; TREATMENT OUTCOME; VISUAL ACUITY;

ADULT; AGED; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL, HUMANIZED; FEMALE; FLUORESCEIN ANGIOGRAPHY; HUMANS; INTRAVITREAL INJECTIONS; MACULAR EDEMA; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RETINAL VEIN OCCLUSION; RETREATMENT; TOMOGRAPHY, OPTICAL COHERENCE; TREATMENT OUTCOME; VISUAL ACUITY;

EID: 84859006955     PISSN: 00303755     EISSN: 14230267     Source Type: Journal    
DOI: 10.1159/000334906     Document Type: Article

References (28)

1. Mitchell P, Smith W, Chang A: Prevalence and associations of retinal vein occlusion in Australia. The Blue Mountains Eye Study. Arch Ophthalmol 1996; 114: 1243-1247. (Pubitemid 26338856)
2. Klein R, Klein BE, Moss SE, Meuer SM: The epidemiology of retinal vein occlusion: the Beaver Dam Eye Study. Trans Am Ophthalmol Soc 2000; 98: 133-141.
3. Rogers S, McIntosh RL, Cheung N, Lim L, Wang JJ, Mitchell P, et al: The prevalence of retinal vein occlusion: pooled data from population studies from the United States, Europe, Asia, and Australia. Ophthalmology 2010; 117: 313-319.
4. The Branch Vein Occlusion Study Group: Argon laser photocoagulation for macular edema in branch vein occlusion. Am J Ophthalmol 1984; 98: 271-282.
5. The Central Vein Occlusion Study Group: Evaluation of grid pattern photocoagulation for macular edema in central vein occlusion. Ophthalmology 1995; 102: 1425-1433.
6. Avitabile T, Longo A, Reibaldi A: Intravitreal triamcinolone compared with macular laser grid photocoagulation for the treatment of cystoid macular edema. Am J Ophthalmol 2005; 140: 695-702.
7. Karacorlu M, Karacorlu SA, Ozdemir H, Senturk F: Intravitreal triamcinolone acetonide for treatment of serous macular detachment in central vein occlusion. Retina 2007; 27: 1026-1030. (Pubitemid 350304002)
8. Gregori NZ, Rosenfeld PJ, Puliafito CA, Flynn HW Jr, Lee JE, Mavrofrides EC, et al: One-year safety and efficacy of intravitreal triamcinolone acetonide for the management of macular edema secondary to central vein occlusion. Retina 2006; 26: 889-895. (Pubitemid 44547441)
9. Aiello LP, Avery RL, Arrigg PG, Keyt BA, Jampel HD, Shah ST, et al: Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. N Engl J Med 1994; 331: 1480-1487. (Pubitemid 24356306)
10. Prager F, Michels S, Kriechbaum K, Georgopoulos M, Funk M, Geitzenauer W, et al: Intravitreal bevacizumab (Avastin) for macular oedema secondary to retinal vein occlusion: 12-month results of prospective clinical trial. Br J Ophthalmol 2009; 93: 452-456.
11. Ahmadi AA, Chuo JY, Banashkevich A, Ma PE, Maberley DA: The effects of intravitreal bevacizumab on patients with macular edema secondary to branch retinal vein occlusion. Can J Ophthalmol 2009; 44: 154-159.
12. Iturralde D, Spaide RF, Meyerle CB, Klancnik JM, Yannuzzi LA, Fisher YL, et al: Intravitreal bevacizumab (Avastin) treatment of macular edema in central retinal vein occlusion: a short-term study. Retina 2006; 26: 279-284. (Pubitemid 44318180)
13. Brown DM, Campochiaro PA, Bhisitkul RB, Ho AC, Gray S, Saroj N, et al: Sustained benefits from ranibizumab for macular edema following branch retinal vein occlusion: 12-month outcomes of a phase III study. Ophthalmology 2011; 118: 1594-1602.
14. Campochiaro PA, Brown DM, Awh CC, Lee SY, Gray S, Saroj N, et al: Sustained benefits from ranibizumab for macular edema following central retinal vein occlusion: twelvemonth outcomes of a phase III study. Ophthalmology 2011; 118: 2041-2049.
15. Wong TY, Scott IU: Clinical practice. Retinal- vein occlusion. N Engl J Med 2010; 363: 2135-2144.
16. Jaissle GB, Leitritz M, Gelisken F, Ziemssen F, Bartz-Schmidt KU, Szurman P: One-year results after intravitreal bevacizumab therapy for macular edema secondary to branch retinal vein occlusion. Graefes Arch Clin Exp Ophthalmol 2009; 247: 27-33.
17. Pece A, Isola V, Piermarocchi S, Calori G: Efficacy and safety of anti-vascular endothelial growth factor (VEGF) therapy with intravitreal ranibizumab (Lucentis) for naive retinal vein occlusion: 1-year follow-up. Br J Ophthalmol 2011; 95: 56-68.
18. Zhang H, Liu ZL, Sun P, Gu F: Intravitreal bevacizumab for treatment of macular edema secondary to central retinal vein occlusion: eighteen-month results of a prospective trial. J Ocul Pharmacol Ther 2011; 27: 615-621.
19. Spaide RF, Chang LK, Klancnik JM, Yannuzzi LA, Sorenson J, Slakter JS, et al: Prospective study of intravitreal ranibizumab as a treatment for decreased visual acuity secondary to central retinal vein occlusion. Am J Ophthalmol 2009; 147: 298-306.
20. Quinlan PM, Elman MJ, Bhatt AK, Mardesich P, Enger C: The natural course of central retinal vein occlusion. Am J Ophthalmol 1990; 110: 118-123. (Pubitemid 20242332)
21. The Central Vein Occlusion Study Group: Natural history and clinical management of central retinal vein occlusion. Arch Ophthalmol 1997; 115: 486-491.
22. Tso MO: Pathology of cystoid macular edema. Ophthalmology 1982; 89: 902-915. (Pubitemid 12019474)
23. Murakami T, Tsujikawa A, Ohta M, Miyamoto K, Kita M, Watanabe D, et al: Photoreceptor status after resolved macular edema in branch retinal vein occlusion treated with tissue plasminogen activator. Am J Ophthalmol 2007; 143: 171-173. (Pubitemid 44917821)
24. Ota M, Tsujikawa A, Murakami T, Kita M, Miyamoto K, Sakamoto A, et al: Association between integrity of foveal photoreceptor layer and visual acuity in branch retinal vein occlusion. Br J Ophthalmol 2007; 91: 1644-1649. (Pubitemid 350207392)
25. Ota M, Tsujikawa A, Murakami T, Yamaike N, Sakamoto A, Kotera Y, et al: Foveal photoreceptor layer in eyes with persistent cystoid macular edema associated with branch retinal vein occlusion. Am J Ophthalmol 2008; 145: 273-280.
26. Ota M, Tsujikawa A, Kita M, Miyamoto K, Sakamoto A, Yamaike N, et al: Integrity of foveal photoreceptor layer in central retinal vein occlusion. Retina 2008; 28: 1502-1508.
27. Sakamoto A, Tsujikawa A, Ota M, Yamaike N, Kotera Y, Miyamoto K, et al: Evaluation of potential visual acuity in eyes with macular oedema secondary to retinal vein occlusion. Clin Experiment Ophthalmol 2009; 37: 208-216.
28. Ach T, Hoeh AE, Schaal KB, Scheuerle AF, Dithmar S: Predictive factors for changes in macular edema in intravitreal bevacizumab therapy of retinal vein occlusion. Graefes Arch Clin Exp Ophthalmol 2010; 248: 155-159.